Performance

Retatrutide for Body Recomposition: Protocol, Dosing & Performance Use

Retatrutide is emerging beyond weight loss. The triple agonist mechanism -- GIP, GLP-1, and glucagon -- gives it a distinct edge for body recomposition that pure GLP-1s cannot match.

TL;DR -- Retatrutide is emerging as a body recomposition tool in performance communities, not just a weight loss drug. The triple agonist mechanism (GIP + GLP-1 + glucagon) drives fat loss while preserving muscle mass better than pure GLP-1s. Protocol: start 0.5mg weekly, titrate to 2--4mg for recomp.

Triple Mechanism

Why Retatrutide for Body Recomp

Most GLP-1 drugs work one way: suppress appetite. Retatrutide works three ways simultaneously -- and the third pathway is what makes it uniquely suited for recomposition.

GLP-1 agonism -- appetite suppression and slow gastric emptying. Shared with semaglutide and tirzepatide. Reduces caloric intake without willpower.

GIP agonism -- enhances fat oxidation directly in adipose tissue. Additive to GLP-1 effects. Also shared with tirzepatide (Mounjaro/Zepbound).

Glucagon agonism -- the key differentiator. Activates brown adipose tissue, increases resting energy expenditure, and drives hepatic fat clearance. This is what makes retatrutide superior for recomp. Tirzepatide has none of this.

Net result: more fat loss per pound of lean mass lost vs semaglutide or tirzepatide. The glucagon component drives preferential fat oxidation rather than equal catabolism of fat and muscle.

Comparison

Retatrutide vs Tirzepatide for Recomp

Both are multi-agonists. The glucagon receptor is the deciding factor for recomposition.

Factor	Retatrutide	Tirzepatide
Agonist targets	GIP + GLP-1 + Glucagon	GIP + GLP-1
Resting energy expenditure	Increases (glucagon)	Minimal effect
Fat loss (trial data)	~17--24% body weight	~15--22% body weight
Muscle preservation	Strong	Good
GI side effects	Similar	Similar
Development stage	Phase 2/3 trials	FDA approved
Reconstitution	Yes (lyophilized)	Yes (lyophilized)

Dosing Guide

Body Recomp Protocol

Titrate slowly. GI side effects are dose-dependent and front-loaded at each escalation step. Rushing the ramp defeats the purpose.

Week 1--4

0.5mg subcutaneous weekly -- tolerance building phase

Week 5--8

1.0mg weekly -- appetite suppression fully active

Week 9--12

2.0mg weekly -- recomp effects become noticeable

Recomp target

2--4mg weekly -- recomp sweet spot reported in community protocols

Maximum studied

4mg weekly -- highest dose in Phase 2 trial

Injection site

Subcutaneous -- abdomen, thigh, or upper arm

Cycle length

Many performance users run 12--16 weeks pre-competition or pre-cycle as a cutting phase

Community Use

Why Performance Communities Are Adopting It

The crossover between GLP-1 drug users and fitness/performance communities is well documented on Reddit and forums like r/Retatrutide and r/moreplatesmoredates. The reasoning is straightforward.

Preferential fat oxidation -- unlike pure GLP-1s which can cause muscle loss alongside fat, retatrutide's glucagon component drives fat as the primary fuel source. You lose fat, not muscle -- the recomp holy grail.

Pre-cycle cutting agent -- get lean first, then blast anabolic compounds with a cleaner body composition baseline. Starting a cycle at lower body fat improves the lean-to-fat gain ratio.

Stack consideration -- some users combine with low-dose GHK-Cu or BPC-157 for connective tissue support during rapid fat loss phases, when tendons and ligaments may be under increased stress.

Community consensus: r/Retatrutide and r/moreplatesmoredates users consistently report the glucagon component as the differentiator vs tirzepatide. The "I kept my muscle" narrative is the most common retatrutide recomp report, vs the more mixed lean-mass outcomes seen on semaglutide.

How to Mix

Reconstitution Guide

Retatrutide is sold as lyophilized (freeze-dried) powder. You add bacteriostatic water to reconstitute before injection. Use the ASCEND calculator to confirm your draw volume.

Typical vial sizes: 2mg or 5mg lyophilized powder

Diluent: Add 1--2mL bacteriostatic water for injection (BAC water)

2mg vial + 1mL BAC water = 2000mcg/mL -- each 0.1mL = 200mcg (0.2mg)

5mg vial + 2mL BAC water = 2500mcg/mL -- each 0.1mL = 250mcg (0.25mg)

Syringe: Use U-100 insulin syringe. Draw volume from ASCEND calculator below.

Storage: Refrigerate at 2--8C. Use within 28 days of reconstitution. Never freeze.

Use the ASCEND Retatrutide calculator -- enter your vial size, BAC water volume, and weekly dose. It outputs the exact IU draw on a U-100 syringe with no math needed.

Safety

Side Effects Specific to Recomp Users

Most side effects are shared with other GLP-1 class drugs. Two -- blood glucose and heart rate -- are specific to the glucagon component and matter more for performance users.

GI side effects -- nausea and slow gastric emptying same as GLP-1 class. Worse at start of each dose increase. Eat smaller meals, avoid high-fat foods during escalation weeks.

Transient blood glucose rise -- glucagon component can raise blood glucose transiently after injection. Monitor closely if diabetic or insulin-resistant. Usually normalizes within hours.

Gallstone risk -- rapid fat loss with any GLP-1 class drug increases gallstone risk. Stay hydrated and maintain adequate fat intake to keep bile flowing.

Hair thinning (telogen effluvium) -- from rapid weight loss, not the drug itself. Usually self-limiting at 3--6 months as the body adjusts.

Heart rate increase -- glucagon mildly raises resting HR at higher doses (3--4mg). Monitor if you have any cardiac history or are sensitive to elevated HR during training.

FAQ

Common Questions

Is retatrutide better than tirzepatide for body recomp?

For body recomposition specifically, retatrutide has advantages due to its glucagon receptor agonism. The glucagon component activates brown adipose tissue, increases resting energy expenditure, and drives preferential fat oxidation -- effects tirzepatide does not produce. Phase 2 data showed slightly greater total weight loss (17--24% vs 15--22%) with a more favorable lean mass retention ratio. That said, tirzepatide is FDA approved and more widely studied -- the decision involves regulatory status, not just mechanism.

What dose of retatrutide for cutting?

The recomp sweet spot reported in performance communities is 2--4mg subcutaneous weekly. Most protocols start at 0.5mg for 4 weeks, escalate to 1mg for 4 weeks, then to 2mg. The maximum dose studied in Phase 2 trials was 4mg weekly. Above 4mg there is no studied safety data.

Can I stack retatrutide with other peptides?

Some performance users combine retatrutide with low-dose BPC-157 or GHK-Cu for connective tissue support during rapid fat loss phases. These are not formally studied combinations. Stacking with other GLP-1 or glucagon agonists would be redundant and increase side effect risk. Always start retatrutide alone to establish your individual response before adding other compounds.

How fast does retatrutide work for fat loss?

In Phase 2 trials, meaningful weight loss was observed by weeks 4--8 at lower doses, with maximal effect by weeks 24--36 at 4mg. Performance users report noticeably reduced appetite within the first 1--2 weeks. Visible body composition changes typically appear at 6--8 weeks on an effective dose (2mg+). The glucagon-driven resting energy expenditure increase adds a metabolic burn on top of calorie restriction.

Does retatrutide cause muscle loss?

Retatrutide causes less muscle loss per pound of total weight lost compared to pure GLP-1 agonists like semaglutide. The glucagon component drives preferential fat oxidation rather than muscle catabolism. Phase 2 data showed a more favorable lean mass retention ratio vs semaglutide. That said, any significant caloric deficit carries some lean mass loss risk -- adequate protein intake and resistance training are the key countermeasures.

Calculate Retatrutide Dose GLP-1 Side Effects Guide

Calculator

Tirzepatide Dose Calculator

GIP + GLP-1 dual agonist -- FDA approved

Guide

GLP-1 Side Effects Guide

Managing nausea, GI effects + more